Stock Research for ADMA

ADMA

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ADMA Stock Chart & Research Data

The ADMA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADMA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ADMA Due diligence Resources & Stock Charts

The ADMA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADMA Detailed Price Forecast - CNN Money CNN View ADMA Detailed Summary - Google Finance
Yahoo View ADMA Detailed Summary - Yahoo! Finance Zacks View ADMA Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ADMA Trends & Analysis - Trade-Ideas Barrons View ADMA Major Holders - Barrons
NASDAQ View ADMA Call Transcripts - NASDAQ Seeking View ADMA Breaking News & Analysis - Seeking Alpha
Spotlight View ADMA Annual Report - CompanySpotlight.com OTC Report View ADMA OTC Short Report - OTCShortReport.com
TradeKing View ADMA Fundamentals - TradeKing Charts View ADMA SEC Filings - Bar Chart
WSJ View Historical Prices for ADMA - The WSJ Morningstar View Performance/Total Return for ADMA - Morningstar
MarketWatch View the Analyst Estimates for ADMA - MarketWatch CNBC View the Earnings History for ADMA - CNBC
StockMarketWatch View the ADMA Earnings - StockMarketWatch MacroAxis View ADMA Buy or Sell Recommendations - MacroAxis
Bullish View the ADMA Bullish Patterns - American Bulls Short Pains View ADMA Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ADMA Stock Mentions - StockTwits PennyStocks View ADMA Stock Mentions - PennyStockTweets
Twitter View ADMA Stock Mentions - Twitter Invest Hub View ADMA Investment Forum News - Investor Hub
Yahoo View ADMA Stock Mentions - Yahoo! Message Board Seeking Alpha View ADMA Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ADMA - SECform4.com Insider Cow View Insider Transactions for ADMA - Insider Cow
CNBC View ADMA Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADMA - OTC Markets
Yahoo View Insider Transactions for ADMA - Yahoo! Finance NASDAQ View Institutional Holdings for ADMA - NASDAQ


Stock Charts

FinViz View ADMA Stock Insight & Charts - FinViz.com StockCharts View ADMA Investment Charts - StockCharts.com
BarChart View ADMA Stock Overview & Charts - BarChart Trading View View ADMA User Generated Charts - Trading View


Latest Financial News for ADMA

Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111
Posted on Wednesday June 13, 2018

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 12) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...


ADMA Biologics Announces Closing of $40M Public Offering
Posted on Tuesday June 12, 2018

RAMSEY, N.J. and BOCA RATON, Fla., June 12, 2018-- ADMA Biologics, Inc. announced today the closing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a ...


ADMA Biologics Announces Pricing of Public Offering of Common Stock
Posted on Friday June 08, 2018

ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) announced today the pricing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share, resulting in gross proceeds of approximately $40.0 million before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on June 12, 2018, subject to the satisfaction of customary closing conditions.  The Company has also granted the underwriters a 30-day option to purchase up to 1,255,230 additional shares of common stock at the public offering price before deducting underwriting discounts and commissions. ADMA intends to use the net proceeds from this offering (i) for continued remediation and ongoing improvement and enhancements at its plasma fractionation facility located in Boca Raton, FL, (ii) to submit the Prior Approval Supplement for, and relaunch of, Bivigam®, (iii) to resubmit the Biologics License Application for its lead pipeline product candidate, RI-002, (iv) in connection with U.S. Food and Drug Administration approval of its third plasma collection facility, and (v) for general corporate purposes and other capital expenditures.


ADMA Biologics Announces Proposed Public Offering of Common Stock
Posted on Thursday June 07, 2018

ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) announced today that it has commenced an underwritten public offering of its common stock.  The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering.  The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Raymond James & Associates, Inc. is acting as the sole book-running manager of the proposed offering.


Enter a stock symbol to view the stock details.